KPV (Alpha-MSH Fragment)
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
200 – 500 mcg
Compound profile
Scientific & efficacy data
Healing & Recovery
Peptide profile
Strong human trials
KPV (Alpha-MSH Fragment)
200 mcg · Once daily
Molecular formula
C16H30N4O4
- Mol. weight
- 342.43 Da
- CAS number
- 67727-97-3
- PubChem
- 125672
- Developed · 2002
- Peptech Ltd research team
Peptech Ltd (later Transition Therapeutics)
Amino acid sequence
Lys-Pro-Val (alpha-MSH residues 11-13)Anti-Inflammatory
Potent NF-κB and MAP kinase pathway inhibitor that significantly reduces TNF-α, IL-1β, and IL-6 at nanomolar concentrations in preclinical IBD models
Gut Health
Selectively targets inflamed intestinal epithelium via PepT1 transporter with demonstrated efficacy in DSS and TNBS colitis models
Healing & Recovery
Preserves intestinal epithelial barrier integrity, reduces inflammatory infiltration, and promotes tissue recovery in damaged mucosal tissue
Dosing
How much do I take?
200 – 500 mcg · once daily · subcutaneous
200 – 500 mcg
Once daily
Covers all 4 documented dose levels · 3 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for inflammatory bowel disease research & gut anti-inflammatory therapy development
Best for
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare KPV (Alpha-MSH Fragment) with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Oral · Subcutaneous injection
Route
KPV (Alpha-MSH Fragment) is administered Oral—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
5 common side effects · 2 serious
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data.
The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation.
Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
KPV safety data come from in vitro mechanistic studies, rodent models, and limited human topical application research. Published research in Journal of Neuroimmunology demonstrates selective anti-inflammatory activity without systemic toxicity signals in animal models.
Human safety data are restricted primarily to pilot studies and unpublished investigations, placing KPV in the research compound category with incomplete clinical characterization. Animal studies show no organ toxicity or genotoxicity at relevant doses.
Common side effects · experienced by some users
Injection Site Reaction
Potential mild redness, swelling, or discomfort at subcutaneous injection site as expected with peptide administration
Management: Rotate injection sites; apply ice if needed; standard subcutaneous injection technique
Mild GI Effects
Theoretical mild gastrointestinal symptoms with oral administration as peptide interacts with intestinal epithelium
Management: Take with food if GI discomfort occurs; start with lower doses and titrate upward
Transient Skin Effects
With topical application, potential mild irritation or redness at application site during initial use
Management: Patch test before widespread application; reduce concentration if irritation occurs
Mild Immune Modulation
Anti-inflammatory effects may transiently alter local immune responses at sites of inflammation
Management: Monitor for signs of infection; effects are expected to be reversible upon discontinuation
Peptide Stability Concerns
As a small peptide, KPV is susceptible to proteolytic degradation which may affect bioavailability rather than cause side effects
Management: Use nanoparticle or hydrogel formulations for improved stability; subcutaneous route may offer better bioavailability than oral
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with KPV (Alpha-MSH Fragment)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
KPV (Alpha-MSH Fragment) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:BPC-157 — Complementary gut-healing peptide that promotes mucosal repair while KPV addresses underlying inflammation
- Safe:Thymosin Alpha-1 — Immune-modulating peptide that can complement KPV anti-inflammatory effects for balanced immune regulation
- Safe:L-Glutamine — Amino acid that supports intestinal barrier function and mucosal integrity alongside KPV anti-inflammatory action
With medications
- Caution:High-Dose Immunosuppressants — Additive immune suppression may increase infection risk through overlapping anti-inflammatory mechanisms
- Caution:Melanotan Peptides — Potential overlapping melanocortin receptor activation could produce unpredictable combined effects
- Caution:Systemic Corticosteroids — Redundant anti-inflammatory pathways may confound therapeutic outcomes or cause excessive immune suppression
With supplements
- Safe:Multivitamins — Generally safe to take alongside KPV (Alpha-MSH Fragment). Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs initial response (1-2 weeks)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
KPV is a three-amino-acid peptide that suppresses inflammatory responses in your immune system.
It works by reducing pro-inflammatory signals and modulating immune cells, making it useful for treating inflammatory skin conditions. KPV calms overactive immune responses without suppressing overall immunity, offering anti-inflammatory benefits similar to steroids but through a safer mechanism.
The deeper mechanism
KPV (lysine-proline-valine) is a tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH) that functions as a potent anti-inflammatory agent through multiple mechanisms.
KPV inhibits NF-κB-dependent pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) in activated macrophages and epithelial cells, reduces mast cell degranulation and histamine release, and activates anti-inflammatory IL-10 production.
Unlike broad immunosuppressants, KPV selectively dampens Th1 and Th17 responses while preserving Th2 and regulatory T cell populations, achieving immunomodulation rather than immunosuppression.
KPV acts through melanocortin receptors (particularly MC1R on immune cells) and TLR4-dependent signaling to reduce NF-κB nuclear translocation. This mechanism makes KPV effective for inflammatory dermatitis, bacterial lip infections (impetigo), and inflammatory intestinal conditions.
What to expect
Initial Response (1-2 Weeks)
What you might notice
- Anti-inflammatory signaling initiated;
- reduction in acute inflammatory markers;
- early improvement in intestinal symptoms in research models
What's normal
- Full integration of KPV (Alpha-MSH Fragment) into physiological systems is established
- Long-term KPV (Alpha-MSH Fragment) response remains personalized to your physiology
- KPV (Alpha-MSH Fragment) tolerance is well-maintained with consistent dosing
What's next
- Maintain your established KPV (Alpha-MSH Fragment) protocol for sustained benefits
- Continue periodic monitoring to confirm KPV (Alpha-MSH Fragment) efficacy
- Review comprehensive KPV (Alpha-MSH Fragment) response with your provider
Active Anti-Inflammatory Phase (2-6 Weeks)
What you might notice
- Significant cytokine reduction;
- improved intestinal barrier function;
- measurable reduction in myeloperoxidase activity and inflammatory infiltrates
What's normal
- KPV (Alpha-MSH Fragment) has achieved stable, long-term homeostatic integration
- Sustained efficacy of KPV (Alpha-MSH Fragment) remains consistent
- Chronic KPV (Alpha-MSH Fragment) effects remain stable and predictable
What's next
- Maintain your established KPV (Alpha-MSH Fragment) protocol for sustained benefits
- Continue periodic monitoring to confirm KPV (Alpha-MSH Fragment) efficacy
- Review comprehensive KPV (Alpha-MSH Fragment) response with your provider
Sustained Benefit (6-12 Weeks)
What you might notice
- Maximum anti-inflammatory and barrier-protective effects;
- prevention of disease progression in chronic models;
- potential for mucosal healing
What's normal
- Full therapeutic effects of KPV (Alpha-MSH Fragment) are well-characterized at this point
- Maintenance of KPV (Alpha-MSH Fragment)'s therapeutic effects is typical
- Tolerance patterns with KPV (Alpha-MSH Fragment) are generally stable over months
What's next
- Comprehensive assessment of KPV (Alpha-MSH Fragment) efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to KPV (Alpha-MSH Fragment) over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
How is KPV related to alpha-MSH?
KPV consists of the last three amino acids (Lys-Pro-Val, positions 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). While it does not contain the melanocortin receptor pharmacophore of the parent hormone, it retains potent anti-inflammatory properties through NF-κB and MAP kinase pathway inhibition, making it the minimal anti-inflammatory fragment of alpha-MSH.
Why is KPV particularly promising for inflammatory bowel disease?
KPV has a unique advantage for IBD because it is selectively transported into intestinal epithelial cells and immune cells by the PepT1 transporter, which is significantly upregulated during intestinal inflammation. This provides targeted delivery to inflamed tissue with minimal systemic effects. Studies show approximately 50% reduction in colonic myeloperoxidase activity in colitis models.
Can KPV be taken orally?
Yes, KPV has demonstrated oral efficacy in preclinical models when added to drinking water at concentrations of approximately 100 micromolar. However, as a small peptide, it is susceptible to proteolytic degradation. Advanced delivery systems including hyaluronic acid-functionalized nanoparticles and hydrogel formulations have been developed to improve oral bioavailability.
Is KPV FDA approved?
No, KPV is not FDA approved for any indication. It remains a research compound with strong preclinical evidence but no published Phase 1-2 human clinical trials. It is available commercially as a research peptide and is used in investigational settings.
How does KPV compare to existing IBD medications?
In preclinical models, KPV offers potential advantages over current IBD treatments. Unlike systemic immunosuppressants, it targets inflammation locally through PepT1-mediated uptake. Unlike biologics targeting single cytokines, KPV inhibits the upstream NF-κB pathway affecting multiple inflammatory mediators. It has shown efficacy without observed adverse effects, though direct human comparisons are not yet available.
What delivery methods have been studied for KPV?
Three main delivery approaches have been investigated: direct oral administration in solution, hyaluronic acid-functionalized nanoparticles (which efficiently target inflamed gut mucosa), and cysteamine-grafted gamma-polyglutamic acid hydrogels (which stabilize the peptide and provide controlled release). Nanoparticle formulations have shown the most promise for enhancing oral bioavailability and targeting efficacy.
Further reading
History & related research
History · since 2001
A tiny piece of nature's anti-inflammatory switch found in hormones
KPV is a three-amino-acid fragment that fights inflammation throughout the body. It comes from a larger hormone called alpha-MSH but works better than the full hormone for treating gut inflammation.
Read the full history of KPV (Alpha-MSH Fragment)Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for KPV (Alpha-MSH Fragment), on one page.